ArticleBMC complementary medicine and therapies2026
The effect of resveratrol on the hippocampus in the pentylenetetrazol (PTZ) - dependent kindling model of epilepsy.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsEpilepsy is a long-term neurological condition marked by neuronal excitotoxicity, oxidative stress, and inflammation of the nervous system. This study seeks to explore the neuroprotective and anti-seizure properties of Resveratrol (RSV) and the molecular processes involved in a pentylenetetrazol (PTZ)-induced kindling epilepsy model, with a focus on ion channels, apoptosis, and SIRT1 pathway.
methodsA total of thirty-two Wistar albino rats were assigned into four groups: Sham, RSV, PTZ, and PTZ + RSV. Following kindling induction via PTZ (35 mg/kg, 3 days/week) or equivalent saline administration for control groups, subsequent RSV treatment (5 mg/kg/day, i.p.) or saline was administered for 28 days. Brain tissues were harvested 24 h after the final injection. Epileptic activity was captured through the use of electrocorticography (ECoG), while tissue damage to the hippocampus was evaluated via hematoxylin-eosin (H&E) staining. Molecular levels of SIRT1, Caspase-3, and S100B protein were assessed via immunofluorescence, whereas SERCA2a, CACNA1G, HCN2, Caspase-3, Caspase-9, and SIRT1 gene expression levels were measured through qPCR analysis.
resultsRSV treatment greatly extended the initial myoclonic jerk delay (p = 0.0001) and lowered both the seizure phase and total spike count compared to the PTZ group. Microscopic examination revealed that RSV maintained tissue health by reducing neuronal deterioration and inflammation in the hippocampal CA1 area. Immunofluorescence analysis revealed that RSV treatment restored SIRT1 levels, which were previously diminished by PTZ, and significantly reduced the elevated markers of apoptosis and glial activation. Furthermore, qPCR analysis demonstrated that RSV treatment significantly reversed PTZ-induced gene expression alterations by upregulating the expressions of SERCA2α, CACNA1G, HCN2, and SIRT1 (p < 0.0001), while downregulating the expressions of Caspase-3 and Caspase-9.
conclusionRSV exerts significant neuroprotective effects in the PTZ kindling model by modulating the SIRT1-mediated stress response and preventing neuronal apoptosis. Notably, this study provides the first in vivo evidence that RSV modulates SERCA2a, CACNA1G, and HCN2 ion channel gene expressions to control intracellular calcium balance and neuronal excitability during epileptogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.